SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

January 04, 2011 09:00 ET

Cleveland BioLabs to Present at Sidoti Microcap Conference

BUFFALO, NY--(Marketwire - January 4, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Sidoti Microcap Conference, January 10, in New York City.

Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland BioLabs, will give a presentation on January 10, at 11:20 a.m. Eastern Daylight Time. The presentation will be available on the Company's website at www.cbiolabs.com under the Investors tab.

Cleveland BioLabs is developing a pipeline of products for multiple defense and medical applications from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation and chemotherapy. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer agents. 

For more information about the Sidoti Microcap Conference, go to: http://microcap.sidoti.com/

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com